Phadia First Company To Receive FDA Clearance Of Recombinant Allergen Component Tests

Wednesday, Sep. 7th 2011 6:40 AM

Phadia, the global leader in allergy and autoimmunity diagnostics, today announced the FDA clearance of recombinant ImmunoCAP® Allergen Components for marketing in the United States. The FDA clearance applies to all of Phadia’s instrument platforms.

Posted on Wednesday, Sep. 7th 2011 6:40 AM | by Share of Cost | in Share of Cost | Comments Off on Phadia First Company To Receive FDA Clearance Of Recombinant Allergen Component Tests